Dong-A ST's new type 2 diabetes therapy Suganon (evogliptin) has been approved in South Korea where it is set to compete with a number of already marketed DPP-4 inhibitors in an increasingly crowded sector. The domestic approval follows global licensing out deals for the drug in the past few years in other markets including China, India, Brazil and Russia.
SEOUL - Dong-A ST Co. Ltd. is set to launch its new diabetes therapy Suganon (evogliptin; DA-1229) in South Korea, where multiple pharma firms are now challenging the crowded dipeptidyl peptidase-4 (DPP-4) inhibitor space.
The affiliate of Dong-A Socio Holdings has received approval from the Ministry of Food and Drug Safety (MFDS) for the...